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Background: We hypothesized that SRX246, a vasopressin V1a receptor antagonist,
blocks the effect of intranasally administered vasopressin on brain processing of angry
Ekman faces. An interaction of intranasal and oral drug was predicted in the amygdala.
Methods: Twenty-nine healthy male subjects received a baseline fMRI scan while they
viewed angry faces and then were randomized to receive oral SRX246 (120mg PO twice
a day) or placebo. After an average of 7 days of treatment, they were given an acute dose
of intranasal vasopressin (40 IU) or placebo and underwent a second scan. The primary
outcome was BOLD activity in the amygdala in response to angry faces. Secondary
analyses were focused on ROIs in a brain regions previously linked to vasopressin
signaling.
Results: In subjects randomized to oral placebo-intranasal vasopressin, there was a
significantly diminished amygdala BOLD response from the baseline to post-drug scan
compared with oral placebo-intranasal placebo subjects. RM-ANOVA of the BOLD
signal changes in the amygdala revealed a significant oral drug × intranasal drug ×
session interaction (F(1, 25) = 4.353, p < 0.05). Follow-up tests showed that antagonism of
AVPR1a with SRX246 blocked the effect of intranasal vasopressin on the neural response
to angry faces. Secondary analyses revealed that SRX246 treatment was associated
with significantly attenuated BOLD responses to angry faces in the right temporoparietal
junction, precuneus, anterior cingulate, and putamen. Exploratory analyses revealed that
the interactive and main effects of intranasal vasopressin and SRX246 were not seen for
happy or neutral faces, but were detected for aversive faces (fear + anger) and at a trend
level for fear faces.
Conclusion: We found confirmatory evidence that SRX246 has effects on the amygdala
that counter the effects of intranasal vasopressin. These effects were strongest for angry
faces, but may generalize to other emotions with an aversive quality.
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INTRODUCTION
Vasopressin (AVP) is a mediator of social and emotional behav-
ior in many species (Garrison et al., 2012) including humans,
and it has been suggested that AVP receptor antagonists might
be useful for treating stress-related neuropsychiatric problems
including inappropriate aggression, post-traumatic stress disor-
der, and major depression (Meyer-Lindenberg and Tost, 2012).
The hypothesis that these disorders might respond to AVP antag-
onists is supported by preclinical and clinical studies showing that
CNS vasopressinergic signaling is deregulated in patients with
these indications (reviewed in Simon et al., 2008).
There are two AVP receptor subtypes in the brain that are
potential therapeutic targets: V1a and V1b. Small-molecule V1b
receptor antagonists have thus far not proven effective for the
treatment of depression (Griebel et al., 2012), which may be due
to the relatively low expression and restricted, hypothalamic dis-
tribution of the receptor. In contrast, the V1a receptor is the
dominant CNS subtype and is found throughout the limbic sys-
tem and several cortical regions, providing a strong rationale for
determining the potential role of this receptor in the regulation of
emotion. To this end, SRX246 was developed as a novel, AVPR1a
antagonist that penetrates the blood brain barrier and has CNS
effects in multiple preclinical models (Ferris et al., 2008; Simon
et al., 2008; Fabio et al., 2013). Because there is currently no
PET ligand that can be used to establish AVPR1a target engage-
ment, we felt that it was important to demonstrate that SRX246
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produced CNS effects in humans after oral dosing before com-
mencing clinical trials in patients. This step is in accord with the
growing consensus that evidence of brain penetration and phar-
macological effect is a vital early component of drug development
for CNS indications (reviewed in Griebel and Holsboer, 2012).
Due to the impermeability of the blood-brain barrier to orally
or intravenously administered neuropeptides, human research
regarding central vasopressin signaling has relied on intranasal
administration of vasopressin. After intranasal administration,
a small amount of vasopressin crosses the blood brain bar-
rier (Riekkinen et al., 1987; Born et al., 2002). A series of
human studies has found that intranasally administered vaso-
pressin enhances attention to and memory of emotional facial
expressions (Thompson et al., 2004, 2006), Several recent studies
have examined the effects of intranasal vasopressin on regional
brain activity as measured by the fMRI blood oxygen level depen-
dent (BOLD) response to experimental emotional and social
stimuli. In total, intranasal vasopressin appears to increase the
neural response to socially relevant stimuli in circuits that medi-
ate emotion regulation (subgenual cingulate: Zink et al., 2010
and Brunnlieb et al., 2013b), theory of mind (inferior pari-
etal lobe: Zink et al., 2011; superior temporal sulcus: Brunnlieb
et al., 2013a; posterior cingulate, Brunnlieb et al., 2013b), and
social recognition (lateral septum; Rilling et al., 2012). Notably,
only one of the five studies found evidence for direct vaso-
pressin on amygdala BOLD (Brunnlieb et al., 2013b). The stim-
uli in this study consisted of line drawings of aversive social
interactions, rather than face stimuli. The absence of a direct
effect of intranasal vasopressin on amygdala reactivity to faces
was initially unexpected (Zink et al., 2010), given the a pri-
ori hypothesis that vasopressin would increase amygdala BOLD
response to aversive faces. With regards to vasopressin modu-
lation of amygdala response to face stimuli, indirect effects on
the amygdala were detected when examining functional con-
nectivity of the subgenual to supragenual cingulate (Zink et al.,
2010). Thus, the human vasopressin challenge literature has
found that vasopressin has effects on behavior predicted by pre-
clinical models, increasing reactivity to social stimuli. The brain
imaging literature has found evidence of altered neural func-
tion following vasopressin challenge in a brain regions previ-
ously implicated in social cognition. Because vasopressin as a
pharmacological probe in these studies lacks specificity for the
V1a or V1b receptor, this work has been unable provide spe-
cific information regarding which subtype vasopressin receptor is
involved. Progress in this area would require either vasopressin
V1a or V1b specific agonists safe for human use, or specific
antagonists.
A novel small-molecule vasopressin antagonist (SRX246;
Azevan Pharmaceuticals) with a high degree of selectivity for
the AVPR1a has undergone preclinical and early clinical test-
ing. SRX246 crosses the blood brain barrier and binds to V1a
receptors with a high degree of selectivity (Fabio et al., 2013).
Its ability to selectively target AVPR1a is reflected in its ability
to reverse AVPR1a-mediated stress reactivity and neural response
to intruder threat (Ferris et al., 2008). Because it has under-
gone successful Phase I single-ascending-dose and 14-day mul-
tiple ascending dose clinical trials with a benign safety profile
(detailed in Fabio et al., 2013), it became available for use as a
pharmacological probe of the AVPR1a.
A double-blinded, placebo controlled experiment was con-
ducted using challenge with intranasal vasopressin and treatment
with SRX246, an oral AVPR1a antagonist. We asked normal male
volunteers to look at emotional faces while their brains were
scanned using fMRI. Half of the subjects were then given SRX246
for an average of 7 days, and half were given placebo-containing
capsules. An hour before they were re-scanned, half of the sub-
jects in each condition were given intranasal arginine vasopressin
(AVP). AVP challenge was used to maximize the chance of finding
an effect of AVPR1a blockade in a sample of healthy subjects, who
presumably did not exhibit excessive central AVP signaling. We
then looked for evidence that brain regions were activated when
patients looked at angry faces vs. a fixation point, that vasopressin
affected such activation, and that SRX246 blunted the responses
seen in the presence or absence of AVP. Because the amygdala
is known to express vasopressin AVPR1a receptors (Young et al.,
1999; Huber et al., 2005; Stoop, 2012) and to be activated during
explicit recognition of emotional (including angry) faces (Derntl
et al., 2009), it served as the principal region of interest in the
experiment. Secondary analyses examined effects in additional
candidate regions found to be modulated by vasopressin in pre-
vious research: the temporoparietal junction, precuneus, anterior
cingulate, subgenual cingulate, and putamen.
METHODS
PARTICIPANTS
All study procedures were approved by the Institutional Review
Board of The University of Chicago. All subjects provided writ-
ten, informed consent. Subjects were recruited from the Chicago
region with IRB approved advertisements in local media. Because
of previous literature indicating the possibility of sexually dimor-
phic effects of vasopressin (Thompson et al., 2006), only male
subjects were studied to preserve statistical power. Twenty-nine
healthy male subjects (ages 18–55) were studied after they were
verified to meet inclusion/exclusion criteria by medical exam and
psychiatric screening with semi-structured SCID and SID-P IV
interviews. Inclusion criteria included being medically and psy-
chiatrically healthy, no past history of an Axis I or II psychiatric
disorder, no obstruction of either nostril to the olfactory epithe-
lium, normal screening blood and urine tests, non-smoking,
normal body weight, right handedness, and no current use of
prescription medications or drugs.
EXPERIMENTAL DESIGN
The study was a double-blinded, between subjects design with
two fMRI scanning sessions. The first session occurred before
any drug administration (Session 1). The second session (Session
2) followed randomization, treatment for a minimum of 5 days
with oral SRX246 or placebo, and 45min after acute administra-
tion of intranasal vasopressin or matching placebo (see Figure 1).
A between subjects design was chosen to eliminate possible carry
over effects of SRX246 or IN vasopressin on the fMRI measures.
To mitigate the effect of individual differences in brain reactiv-
ity to face stimuli, the design included the first baseline scan to
evaluate patterns of change from the first to the second scan.
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FIGURE 1 | Study schematic.
Two experimental drugs were administered in double-blinded
fashion: chronic oral SRX246 and acute intranasal (IN) vaso-
pressin, both with placebo counterparts. After the first scan-
ning session (Session 1, described in the next section), subjects
were randomized to receive 5 days of oral SRX246 (120mg by
mouth, twice a day; n = 15) or equivalent dosing of the match-
ing pill placebo (n = 14). The mean of number of days between
the first and second scanning session was 7.3 (SD = 1.3); the
SRX246 and placebo treatments continued until the day of the
second scanning session. The second session began with ran-
domization to either IN AVP or IN placebo. Vasopressin was
prepared by the research pharmacy of the University of Chicago
General Clinical Research Center. Forty IU synthetic vasopressin
(8-arginine-vasopressin, Pitressin, Monarch Pharmaceuticals)
was dispensed using Good Clinical Practices into two intranasal
atomizers (MAD 300; LMA North America Inc., San Diego CA).
IN placebo was prepared from a commercial nasal saline solution
to mask the mild scent of Pitressin solution. IN drug was admin-
istered in 4 puffs (0.2mL) per nostril over 15min by the research
staff to subjects reclining on an exam table with their heads tilted
back. Subjects rested on the examination table by themselves with
the examination room door open until the beginning of the sec-
ond fMRI scanning session, timed to begin 45min after IN drug
administration. This time point was chosen based on the time
course of CSF levels of vasopressin after IN administration (Born
et al., 2002) and to remain consistent with previous fMRI studies
of IN vasopressin effects.
The first and second scanning sessions were identical. In the
scanner, subjects viewed 4 blocks of each emotional facial expres-
sion, using stimuli from the Ekman Pictures of Facial Affect
stimulus set (angry, neutral, happy, fear). The stimuli were pre-
sented over 4 runs. To preserve statistical power, analyses focused
on the neural responses to angry faces, based on a priori hypothe-
ses regarding the relevance of angry faces to vasopressin function.
Each emotion block lasted 20 s and consisted of 5 faces displayed
for 4 s in the center of the screen, with no interstimulus interval.
The behavioral task was to identify the valence of the emotion
(positive, negative, neutral) by button press. An explicit emotion
paradigm was employed based on a large amount of high reso-
lution fMRI data demonstrating that this type of task evokes a
readily detectable amygdala response (Pessoa et al., 2002; Habel
et al., 2007; Derntl et al., 2009; Dyck et al., 2011). Fixation cross
was chosen as a contrast condition rather than neutral faces for
this study in order to maximize statistical power by avoiding the
variability associated with contrasts of emotional faces with neu-
tral faces. Neutral faces also activate the amygdala (Fitzgerald
et al., 2006; Derntl et al., 2009). The extent and variability of this
activation reduces BOLD signal intensity when neutral faces are
used as a contrast condition (Mattavelli et al., 2013) and reduces
the reliability of amygdala response to emotional faces (Johnstone
et al., 2005).
fMRI data were acquired using a Philips Achieva Quasar
3T MRI scanner at the Brain Research Imaging Center at The
University of Chicago. For identification of landmarks and ori-
entation of follow up scans, low-resolution structural MRI was
obtained with a T1-weighted spin-echo sequence (TR = 600ms,
TE = 10ms; FA = 70◦, FOV = 23 cm2, slice thickness/gap =
4.0/0.5). fMRI images were obtained with high-field functional
MRI utilizing T2∗-weighted echo planar imaging with BOLD
(blood oxygenation level dependent) contrast (echo time/TE =
20ms, repetition time/TR of 2000ms, flip angle of 80◦, field of
view of 230mm2, 30 4mm oblique axial slices approximately par-
allel to the AC-PC line, 0.5mm slice gap). A modified high effi-
ciency z-shim compensation was applied to the 4 slices covering
the orbitofrontal cortex (Du et al., 2007) to minimize susceptibil-
ity artifacts. Acceptable signal to noise ratio was confirmed for the
ventral brain and medial temporal lobes.
fMRI data were pre-processed using SPM8 software (Wellcome
Department of Cognitive Neurology, London). Images were band
pass filtered to remove very low frequency drift artifact and
high frequency, non-physiologic noise. Images acquired during
excessive movement (≥3mm X, Y, or Z spatial displacement
and/or 5◦ of rotation) were excluded from the analysis. Motion
in the three planes was recorded and images were motion
corrected relative to the first image of the first run, normal-
ized to a Montreal Neurological Institute template, resampled
to 2mm3 voxels, and smoothed with an 8mm3 kernel. T2∗
functional data of each subject were examined for suscepti-
bility artifacts and/or signal loss near the principal regions of
interest.
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T-statistical images were generated for the first and second
fMRI sessions separately to confirm that the task led to the
expected pattern of regional brain activation. To control for Type
I error, Family Wise Error (FWE) was utilized for the entire brain
region in voxelwide analyses (p < 0.05, cluster size> 10 contigu-
ous voxels). Analyses were focused on angry face contrasts given
the limited power of the study. An exploratory analysis of other
facial emotion conditions is provided in Supplementary Material.
To establish the effect of the IN vasopressin probe in the
principal ROI of the left and right amygdala, data were com-
pared between the IN vasopressin and IN placebo group within
the sub-sample of subjects randomized to oral placebo (n = 14).
One-Way ANOVAwas conducted onwhole-brain contrast images
of angry faces vs. fixation point, with the factors of session and
IN drug; the hypothesized IN drug effect was tested with the
statistical interaction between the two factors by confirming sig-
nificant clusters of activation within the anatomical amygdala.
To balance concerns of Type I and Type II error, correction for
multiple comparisons on significant clusters utilized familywise
error correction (FWE) within the small volume of the anatomic
amygdala as defined by Wake Forest University (WFU) Pickatlas
(Maldjian et al., 2003; p < 0.05, one-tailed). Parameter estimates
(βweights) of average activation were extracted from the anatom-
ical amygdala ROI (WFU Piackatlas) and exported to SPSS 18
(IBM) for statistical analysis. Two separate paired t-tests were
then conducted in the seven subjects receiving intranasal vaso-
pressin and the seven subjects receiving intranasal placebo. To
account for baseline differences, follow up tests were repeated
using ANCOVA to compare IN vasopressin vs. IN placebo on the
extracted Session 2 amygdala BOLD signal, covarying for Session
1 in the 14 subjects receiving oral placebo.
The primary hypothesis of the study, that SRX246 engages
its target by blocking vasopressin effects on the amygdala, was
tested with repeated measures (RM) ANOVA for the interac-
tion of the factors of oral drug (SRX246 vs. oral placebo),
intranasal drug (IN vasopressin vs. IN placebo), side (left vs.
right), and session (Session 1 vs. Session 2) on the extracted
parameter estimates of average amygdala BOLD response to
angry faces. Repeated Measures (RM) ANOVA was conducted
with the between-subjects factors of oral drug and intranasal
drug, with the within-subjects factor session. The statistical sig-
nificance threshold was set at p = 0.05, 2-tailed. Significant main
effects and/or interactions were followed up with appropriate
post-hoc, 2-tailed tests. Paired t-tests were conducted to com-
pare Session 1 and Session 2 BOLD response in the four drug
subgroups. Additionally ANCOVA of Session 2 BOLD response
covarying for Session 1, comparing IN vasopressin to IN placebo
was conducted in subjects randomized to oral SRX246 and oral
placebo.
In exploratory analyses, the effects of SRX246 and vasopressin
on BOLD reactivity were assessed in ROIs previously found to
be modulated by vasopressin or expressing the AVPR1a: sub-
genual cingulate (Zink et al., 2010), anterior and posterior cin-
gulate (Zink et al., 2010), precuneus (Brunnlieb et al., 2013a),
temporoparietal junction (Rilling et al., 2012; Brunnlieb et al.,
2013b), and caudate/putamen (Hammock and Young, 2006).
Voxel-wide, whole brain analysis was performed on Session 2
data, comparing the response to angry faces vs. fixation point
between the SRX246 to oral placebo treatments. ROI analyses
were performed using the corresponding anatomical structure
[Automated Anatomical Atlas (AAL) SPM], with the significance
threshold set at p < 0.05, FWE corrected for the anatomical
search volume. Individual differences in the tortuous gyral/sulcal
morphology of the temporoparietal region make spatial defini-
tions of it unreliable for group analyses (Tzourio-Mazoyer et al.,
2002). Instead, the ROI was a 9mm sphere centered onMNI coor-
dinates reported in the most recent of a series of studies that have
found functional activations in the right temporoparietal junc-
tion during theory of mind related tasks (54,−54, 22; Koster-Hale
et al., 2013). Average activations within these ROIs at Session
2 were extracted as β weights into SPSS for ANCOVA, covary-
ing for baseline differences. Because this is the first fMRI study
of SRX246, exploratory, whole brain exploratory comparisons of
SRX246 vs. placebo on BOLD response to angry faces (vs. fixa-
tion point) during Session were conducted. Uncorrected results
are provided in Table 3.
BEHAVIORAL DATA
Accuracy and reaction time were recorded and analyzed by RM-
ANOVA, with the within subjects factor of session and between
subjects factors of oral and intranasal drug. Significant interac-
tions were followed up with post-hoc t-tests (2-tailed). To relate
the behavioral measures with brain response, change in reaction
time and accuracy (Session 2 – Session 1) was correlated with
change in amygdala BOLD (Session 2 – Session 1).
SIDE EFFECTS
The Adverse Events Questionnaire (AEQ) was used to mea-
sure a range of possible somatic and psychological side effects.
Suicidal symptoms were assessed with the Columbia Suicide
Severity Rating Scale (C-SSRS; validation in Posner et al., 2011).
Depressive symptoms were measured with the Beck Depression
Inventory II (BDI-II; Beck et al., 1996). Differences between drug-
and placebo-treated subjects in safety (vital signs and laboratory
parameters), side effects (AEQ, BDI-II, CSSR-S), and EKG data
(PR interval, QT, QTc) were assessed with a series of separate
RM-ANOVAs for each measure.
RESULTS
TASK-RELATED ACTIVATIONS ON SESSION 1 AND SESSION 2
BOLD responses to angry faces vs. fixation point were observed
in the visual cortex, right and left amygdala, temporal pole,
and ventral prefrontal cortex for Session 1 and 2 (Table 1 for
Session 1, Table 2 and Figure 2 for Session 2). Areas of activa-
tion were within regions expected to show task-related changes
in brain activity. Attenuated intensity and cluster size of BOLD
was observed from Session 1 to Session 2 in the entire sample.
Contrasts of angry faces vs. neutral faces did not result in measur-
able amygdala BOLD signal suitable for analysis of drug related
effects (see Supplementary Material 3.1∗).
EFFECT OF IN VASOPRESSIN
One-Way ANOVA in the subsample of 14 subjects who did not
take SRX246 revealed a significant interaction of session × IN
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Table 1 | Results of voxel-wide whole brain analysis of Session 1 for contrasts of anger vs. fixation point.
Region MNI coordinates Cluster size (voxels) T p(FWE-corrected)
x y z
Occipital gyrus 40 −76 −14 13,574 18.5 <0.001
Right amygdala 20 −4 −20 763 12.47 <0.001
Superior frontal gyrus 12 66 38 1986 11.66 <0.001
Left middle frontal gyrus −46 24 50 139 9.73 <0.001
Left amygdala −18 −6 −14 572 9.5 <0.001
Rectus −6 54 −18 368 9.34 <0.001
Left temporal pole −36 26 −28 195 8.31 <0.001
Right temporal pole 42 20 −34 156 7.56 0.002
Left inferior frontal gyrus −56 34 14 70 7.47 0.002
Left inferior frontal gyrus −54 40 4 118 7.39 0.002
Left inferior temporal gyrus −48 10 −38 64 7.05 0.005
Left orbital frontal gyrus −48 28 −4 62 6.91 0.007
Right inferior frontal gyrus triangular 60 32 2 114 6.8 0.009
Left fusiform −30 −6 −44 11 6.78 0.009
Supplementary motor area −4 14 72 23 6.38 0.023
Clusters of significant activation (>10 contiguous voxels) that survive statistical threshold for multiple comparisons (FWE across the entire brain, p < 0.05).
Table 2 | Results of voxel-wide whole brain analysis of Session 2 for contrasts of anger vs. fixation point.
Region MNI coordinates Cluster size (voxels) T p(FWE-corrected)
x y z
Occipital gyrus 20 −100 4 13,390 16.87 <0.001
Right inferior frontal gyrus triangular 58 30 16 1150 10.98 <0.001
Right amygdala 22 −4 −16 207 10.03 <0.001
Right hippocampus 24 −30 −4 314 9.18 <0.001
Left inferior orbital frontal −50 22 −16 1353 8.82 <0.001
Right inferior orbital frontal 42 34 −14 140 8.38 <0.001
Left hippocampus −20 −34 −2 161 8.12 0.001
Right fusiform 30 −6 −44 52 7.26 0.003
Left cerebellum −16 −78 −40 84 7.22 0.004
Right cerebellum 28 −76 −40 26 7.01 0.005
Right temporal pole 46 20 −30 68 6.93 0.007
Left temporal pole −26 18 −30 23 6.89 0.007
Left amygdala −28 0 −20 11 6.85 0.008
Left amygdala −18 0 −10 48 6.70 0.011
Clusters of significant activation (>10 contiguous voxels) that survive statistical threshold for multiple comparisons (FWE across the entire brain, p < 0.05).
drug within both the left and right amygdala (p < 0.05, FWE cor-
rected for the volume of the region; depicted in Figure 3). Follow-
up paired t-tests comparing amygdala BOLD intensity across the
first and second session revealed that in subjects receiving IN
vasopressin, BOLD signal intensity significantly decreased in the
right amygdala [t(1,6) = −2.560, p < 0.05] and at a trend level
in the average of both sides [t(1,6) = −2.058, p = 0.09], but no
effect was seen in the left amygdala. No significant pairwise dif-
ference in amygdala BOLD between the two sessions was seen
in the subjects receiving IN placebo. ANCOVA of the amyg-
dala BOLD response in subjects receiving oral placebo produced
similar results, with IN vasopressin associated with significantly
decreased BOLD response at Session 2, controlling for Session
1 BOLD response, in the right amygdala [F(1, 13) = 5.013, p <
0.05] and at a trend level for the combined left and right amyg-
dala [F(1, 13) = 4.538, p = 0.057]. No effect was found in the left
amygdala. See Supplementary Material 3.2∗ for analyses of other
emotion conditions.
PRIMARY HYPOTHESIS: INTERACTION OF ORAL SRX246 AND
INTRANASAL VASOPRESSIN ON AMYGDALA BOLD RESPONSE
The primary hypothesis that SRX246 blocks effects of vasopressin
on the amygdala was confirmed. RMANOVA of extracted param-
eter estimates from the left and right amygdala in the entire
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sample revealed a significant 3 way interaction of session × oral
drug × IN drug in contrasts of angry faces vs. fixation point
[F(1, 25) = 4.353, p < 0.05]. Follow up testing of the interaction
in the four drug subgroups with paired t-tests comparing Session
1 to Session 2 BOLD response in the left and right amygdala
confirmed that a significant Session 1 vs. Session 2 difference
was found only in the subgroup of subjects randomized to oral
placebo and IN vasopressin (as described in the Effect of IN
Vasopressin). Subjects randomized to oral SRX246 and IN vaso-
pressin did not show a Session 1 to Session 2 difference [t(1,7) =
0.819, p = 0.44 (Figure 4)]. ANCOVA of Session 2 amygdala
BOLD, covarying for Session 1, confirmed that in subjects taking
oral SRX246, no effect of IN vasopressin was seen in the combined
amygdala [F(1, 14) = 0.384, p = 0.55], right amygdala [F(1, 14) =
0.067, p = 0.8], or left amygdala [F(1, 14) = 1.063, p = 0.32].
There was no main effect of SRX or vasopressin on amygdala
BOLD response. See Supplementary Material 3.3∗ for analyses of
other emotion conditions.
SECONDARY ANALYSES
Cross-sectional, Session 2 comparison of SRX246 (n = 15) vs.
oral placebo (n = 14) revealed clusters of activation that sur-
vived small volume correction in contrasts of angry faces
FIGURE 2 | Regions of BOLD signal intensity for Session 2 angry faces
> fixation point. Results of the Session 2 voxel-wide whole brain analysis
for all subjects (n = 29), angry faces > fixation point, thresholded at
p < 0.001 FWE corrected for the entire brain, cluster size > 10 contiguous
voxels. A similar pattern of BOLD activation is present albeit with
attenuated intensity and size of activated clusters relative to Session 1.
FIGURE 3 | Intranasal drug × session interaction in the region of the
right amygdala. Results of ROI analysis of the amygdala with One-Way
ANOVA in subjects randomized to oral placebo (n = 14). A cluster in the
right amygdala survived statistical thresholding (p < 0.05, FWE corrected
for the small volume of the anatomical amygdala). Pictured are voxels
surviving the statistical threshold an interaction of session (Session 1 >
Session 2) × drug (IN placebo > IN vasopressin). Follow-up testing revealed
that SRX246 blocked the effect of IN vasopressin in the right amygdala.
vs. fixation point within the ROIs of the right sided tem-
poroparietal junction, precuneus, anterior cingulate gyrus, and
putamen.
SRX246 compared with oral placebo was associated with
significantly diminished BOLD signal intensity in the right
temporoparietal junction [p < 0.005, FWE corrected for the
functional ROI in the right temporoparietal junction; t(1,27) =
4.52; cluster size = 107 voxels; 50, −58, 20; Figure 5]. ANCOVA
confirmed that the difference remained significant after con-
trolling for Session 1 BOLD intensity [F(1, 26) = 6.478, p <
0.05].
SRX246 was associated with significantly diminished BOLD
activity in a cluster within the right precuneus (p < 0.05, FWE
corrected for the small volume of the anatomical precuneus,
cluster size = 33 voxels; MNI coordinates = 8, −56, 38;
Figure 6). ANCOVA revealed that the difference remained sig-
nificant after controlling for Session 1 BOLD intensity [F(1, 26) =
6.208, p = 0.02].
FIGURE 4 | Right Amygdala BOLD in the Four Drug Subgroups:
Significant differences are seen in paired t-tests between Session 1
and 2 only in the subgroup of subjects randomized to oral placebo and
intranasal vasopressin (p < 0.05).
FIGURE 5 | SRX246 associated blunting of right TPJ to angry faces. The
cluster (circled in blue) of significantly blunted BOLD response within the
right temporoparietal junction in the subjects randomized to SRX246 vs.
placebo, angry faces > fixation point (p < 0.005, FWE corrected for the
small volume of the function right TPJ, cluster size = 107 voxels; MNI
coordinates = 50, −58, 20).
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SRX246 was associated with reduced BOLD response in a
cluster of the right anterior cingulate [p < 0.05 FWE for small
volume of the right anterior cingulate, t(1,27) = 4.34, cluster
size = 20 voxels; MNI coordinates = 6, 46, 22; Figure 7].
ANCOVA revealed that the difference remained significant after
controlling for Session1 BOLD intensity [F(1, 26) = 14.473, p =
0.001].
SRX246 was associated with reduced BOLD response in two
clusters within the right putamen [p < 0.05, FWE corrected for
small volume, T(1, 27) = 4.7 and 4.55, cluster size = 18 and 17
voxels; MNI coordinates = 22, 2, 8 and 28, 12, −8, respectively;
Figure 8]. ANCOVA revealed the difference remained significant
after controlling for Session 1 BOLD intensity [F(1, 26) = 19.724,
p < 0.001].
Clusters of significant activation from exploratory voxel-wide
whole brain analysis are presented in Table 3, at the uncor-
rected statistical threshold of p < 0.001, one-tailed. No main
effects of IN vasopressin were detected in the above ROIs. See
Supplementary Material 3.4∗ for exploratory analyses of other
emotion conditions.
FIGURE 6 | SRX246 associated blunting of right precuneus to angry
faces. Cluster of significantly blunted BOLD response within the right
precuneus in the subjects randomized to SRX246 vs. placebo, angry faces
> fixation point (p < 0.05, FWE corrected for the small volume of the
anatomical precuneus, cluster size = 33 voxels; MNI coordinates = 8,
−56, 38).
FIGURE 7 | SRX246 associated blunting of right anterior cingulate to
angry faces. SRX246 was associated with reduced BOLD response in a
cluster of the right anterior cingulate [p < 0.05 FWE for small volume of the
right anterior cingulate. t(1, 27) = 4.34, cluster size = 20 voxels; MNI
coordinates = 6, 46, 22].
BEHAVIORAL EFFECTS
For accuracy, RM-ANOVA revealed no main effects or inter-
actions for session, IN drug, or oral drug. For reaction time,
RM-ANOVA revealed a significant effect of time [F(1, 24) = 15.05,
p < 0.05], with reaction time to Angry faces decreasing from
Session 1 (423.41ms, SD = 130.937) to Session 2 (342.414ms,
SD = 158.743). A trend level interaction was detected for session
× oral drug [F(1, 24) = 3.435, p = 0.08]. Follow up testing with
paired t-tests comparing Session 1 to Session 2 revealed that sub-
jects randomized to oral placebo showed a significant decrease in
reaction time to angry faces from Session 1 to Session 2 [t(1,13) =
4.773, p < 0.001]; subjects randomized to SRX246 also showed
a decrease but the difference was not significant [t(1,13) = 1.182,
p = 0.26].
Change in amygdala BOLD response to angry faces (Session
2 – Session 1) was negatively correlated with the change in
number of hits (# correct valence identifications for Session
2 – Session 1). This was true for the average of left and right
amygdala together (r = −0.520, p = 0.005, n = 28), for the
left amygdala (r = −0.462, p = 0.013) and the right amygdala
(r = −0.527, p = 0.004). Thus, the decreased BOLD response
from Session 1 to Session 2 seemed to predict improved
performance. There was no relationship between change in
amygdala BOLD response to angry faces and reaction time
measures.
SAFETY AND SIDE EFFECTS
There were no serious or unexpected adverse events. SRX246
was not associated with change in AEQ subscores, BDI-II, vital
sign parameters, laboratory parameters, CSSR-S score, or urine
specific gravity.
DISCUSSION
Chronic treatment with SRX246, a novel AVPR1a antagonist,
blunts the effect of acute vasopressin administration on the func-
tional response of the amygdala to angry faces in healthy males.
An effect of intranasal vasopressin on subcortical processing of
emotional facial expressions was confirmed: in healthy males,
vasopressin enhanced accommodation, as reflected in a decrease
from Session 1 to Session 2, of the amygdala to angry faces.
This effect was effectively blocked by pretreatment with SRX246.
FIGURE 8 | SRX246 associated blunting of right putamen to angry
faces. SRX246 was associated with reduced BOLD response in two
clusters within the right putamen [p < 0.05, FWE corrected for small
volume, T(1, 27) = 4.7 and 4.55, cluster size = 18 and 17 voxels; MNI
coordinates = 22, 2, 8 and 28, 12, −8, respectively].
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Table 3 | Exploratory findings of regional BOLD signal blunting with SRX246.
Region x y z Cluster size (voxels) T p(uncorrected)
Anterior cingulate/DMPFC 12 40 44 1773 6.41 <0.001
Right inferior temporal 48 −14 −22 227 6.21 <0.001
Right precuneus 8 −56 38 243 5.50 <0.001
Right putamen 18 −2 10 169 5.27 <0.001
Right inferior temporal 44 0 −44 287 5.18 <0.001
Right hippocampus 32 −18 −10 100 5.14 <0.001
Cerebellum 26 −50 −42 290 5.13 <0.001
Cerebellum −28 −42 −42 56 4.76 <0.001
Right putamen 28 12 −8 157 4.55 <0.001
Right superior temporal 50 −58 20 108 4.52 <0.001
Cerebellum 46 −54 −44 13 4.19 <0.001
Right inferior frontal triangular 48 34 4 32 4.01 <0.001
Left putamen −18 6 14 12 3.99 <0.001
Left precuneus −10 −56 46 50 3.98 <0.001
Cerebellum −28 −82 −38 33 3.97 <0.001
Anterior cingulate −4 18 24 10 3.96 <0.001
Left middle temporal −60 −26 −16 23 3.96 <0.001
Right inferior frontal 60 18 16 29 3.95 <0.001
Right fusiform 28 −32 −18 17 3.95 <0.001
Right middle temporal 46 −36 0 62 3.91 <0.001
Cerebellum 18 −48 −24 59 3.90 <0.001
Left inferior frontal triangular −46 20 18 37 3.88 <0.001
Cerebellum −28 −56 −18 45 3.87 <0.001
Cerebellum −18 −66 −42 11 3.80 <0.001
Cerebellum −10 −62 −32 31 3.71 <0.001
Cerebellum −22 −68 −20 20 3.59 0.001
Results of the exploratory whole-brain comparison of SRX246 vs. placebo. Listed are clusters of significant activation (>10 contiguous voxels) within the
corresponding brain structures that survive statistical threshold (p < 0.001, uncorrected for multiple comparisons).
Additional main effects of SRX246 were found on cortical pro-
cessing of angry faces in the right side of the brain within the
ROIs of the temporoparietal junction, precuneus, anterior cingu-
late, and putamen. These novel findings provide the first evidence
for AVPR1a signaling in a neural circuit that mediates processing
of social and emotional information (Saxe and Kanwisher, 2003;
Zink and Meyer-Lindenberg, 2012).
The findings add to a growing literature regarding the role
of vasopressinergic AVPR1a signaling in human social and emo-
tional behavior. Genetic variation in the promoter region of
AVPR1a has been associated with risk for autism, in which social
deficits are the core symptom (Kim et al., 2002; Wassink et al.,
2004). The same genetic polymorphisms have been linked to an
altered functional response of the amygdala to fearful and angry
faces in healthy adults (Meyer-Lindenberg et al., 2009).
Preclinical studies have demonstrated that vasopressin plays
an important role in social recognition. We observed that IN
vasopressin was associated with accommodation of the BOLD
response of the amygdala to angry faces and that SRX246 pre-
treatment blocked this effect. These results are consistent with
a role for vasopressin in social recognition in humans and pro-
vide the first evidence for the involvement of AVPR1a in this
process. The direction of the effect of IN vasopressin, specifically
decreased BOLD signal, differed with a previous animal model
finding suggesting excitation as an expected outcome (Huber
et al., 2005). Two potential explanations for this discrepancy
can be put forward. One is found in rodent models, where
AVPR1a signaling in the lateral septum is a necessary and suf-
ficient condition for social recognition (Allaman-Exertier et al.,
2007). Interestingly, the lateral septum tends to inhibit the amyg-
dala, an action which likely facilitates social approach behaviors
(Thomas et al., 2012). Whether the lateral septum, or its func-
tional human equivalent, facilitates social recognition by suppres-
sion of the amygdala in humans is unknown. The second is that
amygdala habituation to repeated presentation of emotional faces
has been established in humans (Hariri et al., 2002). Our data
indicate that vasopressin signaling through the AVPR1a plays a
role in this process and that AVPR1a antagonism can modulate
this effect.
Secondary analyses of the main effects of SRX246 showed
that treatment with the AVPR1a antagonist reduced the response
to angry faces in the right sided temporoparietal junction,
precuneus, anterior cingulate, and putamen. The inhibitory
effect of AVPR1a blockade on temporoparietal junction acti-
vation to angry faces is consistent with previous findings
of vasopressinergic modulation of this brain region during
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processing of social and emotional information (Zink et al., 2011;
Rilling et al., 2012; Brunnlieb et al., 2013b). The TPJ is involved in
cognitive processes such as theory of mind and psychological per-
spective taking (Saxe and Kanwisher, 2003; Decety and Grezes,
2006) that play a fundamental role in human social interactive
behavior. Hyperactivity has been noted in this region in anx-
ious patients during negative social interactions (McClure-Tone
et al., 2011) and altered function is considered a potential mech-
anism in disorders such as autism (Kana et al., 2012). Given that
the TPJ is responsive to the emotional, social, and moral aspects
(Kret et al., 2011; Koster-Hale et al., 2013) of stimuli involving
social interaction, stress-related over-mentalizing during nega-
tive social interactions, mediated in part through the TPJ, may
be a psychopathological mechanism amenable to treatment with
AVPR1a antagonists. Our results raise the possibility that the TPJ
may represent a novel treatment target in stress related disor-
ders, although an important question in this context is whether
the effects of SRX246 are mediated directly by AVPR1a in the
region itself or indirectly via connected substructures such as the
amygdala, lateral septum, posterior cingulate, or thalamus that,
based on studies in rodents and non-human primates, are known
to express vasopressin receptors (Young et al., 1999; Phelps and
Young, 2003).
AVPR1a modulation of the precuneus is consistent with pre-
vious findings that IN vasopressin increased precuneus activity
during a simulated aggressive social interaction (Brunnlieb et al.,
2013a). Precuneus activity has been reported in fMRI studies of
face processing (metaanalysis in Fusar-Poli et al., 2009), and has
specifically been associated with social recognition (Lee et al.,
2013). In general, the precuneus is thought to play a role in
self-awareness and higher cognitive processes above and beyond
sensory discrimination (reviewed in Cavanna and Trimble, 2006).
The clinical potential of pharmacological modulation of the pre-
cuneus is suggested by a link to biological risk factors for anxiety
and depression (Rogers et al., 2013).
That the AVPR1a antagonist treatment resulted in blunting
of the anterior cingulate response to angry faces is consistent
with previous research. IN vasopressin increases anterior cingu-
late activity during processing of social interactions (Brunnlieb
et al., 2013a) and prevents supragenual cingulate deactivation
during viewing of angry and fearful faces (Zink et al., 2010).
The anterior cingulate is activated by viewing of emotional faces
(Fusar-Poli et al., 2009). Like the precuneus, it is also implicated
in social cognition (reviewed in Frith and Frith, 2003). Increased
reactivity of the anterior cingulate to negatively valenced stim-
uli is a consistent finding in major depressive disorder (reviewed
in Hamilton et al., 2013); thus modulation of the anterior cin-
gulate via AVPR1a antagonism may well have clinical utility. The
putamen expresses vasopressin receptors (Hammock and Young,
2006) and is activated by viewing of angry faces (Strauss et al.,
2005). Our finding that SRX246 blunted the response in this
region is in accord with these findings and indicates a prominent
role for the V1a receptor subtype. A recent review of fMRI stud-
ies of face processing in major depression has found a pattern of
putamen hyperreactivity to angry faces (Stuhrmann et al., 2011).
Future studies should investigate the possibility that blocking
AVPR1a in depressed patients reverses putamen hyperreactivity
to aversive stimuli.
Given the design of the study and results from the exploratory
analyses on the processing of emotions other than anger, the
effects of vasopressin modulation and SRX246 may extend
beyond only angry faces to the processing of aversive emotional
expressions more generally. Such an interpretation would be con-
sistent with the findings of Thompson and others (2006), who
found that intranasal vasopressin increased tone of the corruga-
tor supercilii muscle, a facial expression associated with response
to threat common to anger and fear. This possibility is interest-
ing in terms of potential treatments for stress-related disorders,
but given the limitations of the current study, additional work is
needed to fully characterize the effects of vasopressin and AVPR1a
receptor antagonism on specific emotional responses.
Our study presents the first translational investigation of a
novel, first-in-class AVPR1a antagonist in a vasopressin chal-
lenge, emotional processing paradigm. Some limitations of the
study are worth mentioning regarding the interpretation of
the results. To optimize reliability, the sample was made as
homogenous as possible in terms of age range, gender, and
psychiatric profile. To preserve statistical power for the pri-
mary comparisons, the analysis focused on the amygdala and
contrasts involving angry facial expressions. For feasibility rea-
sons, the study was not powered to detect emotion specific
effects of SRX246. Secondary analyses regarding main effects of
SRX246 were similarly restricted to a subset of brain regions pre-
viously identified to be affected by vasopressin signaling. The
limited power of the study makes it likely that significant effects
of vasopressin and SRX246 on other brain regions were not
detected. Finally, interpretation of the fMRI BOLD signal as
responsive to pharmacological manipulations requires the infer-
ence that the drug has a direct effect on regional brain activ-
ity. While the results, when combined with extensive in vitro
studies that demonstrate exceptional selectivity and selectivity
for the V1a receptor and in vivo results in preclinical mod-
els (e.g., Ferris et al., 2008; Fabio et al., 2013) strongly sug-
gest target engagement, definitive evidence requires studies with
a PET or SPECT ligand. Unfortunately, no such ligands are
available.
In conclusion, the results provide the initial demonstration
in humans that blockade of AVPR1a with SRX246 significantly
reduces the effect of intranasally administered vasopressin on
the response of the amygdala to angry face stimuli as mea-
sured by the fMRI BOLD response. Additional effects of SRX246
were observed on responses in the temporoparietal junction,
putamen, precuneus, and anterior cingulate. These findings
extend a growing body of evidence establishing the impor-
tance of vasopressin signaling in the processing of social and
emotional stimuli. Because exaggerated responses to negatively
valenced emotional stimuli in circuits that include these struc-
tures are characteristic of several stress-related psychiatric dis-
orders, the ability of SRX246, a novel AVPR1a antagonist, to
attenuate the response to angry faces supports the potential of
AVPR1a antagonism as a new approach to the treatment of these
indications.
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